Immunohistologic assessment of technetium-99m-MIBI uptake in benign and malignant breast lesions

Journal of Nuclear Medicine

Volumn 39, Issue 3, 1998, Pages 449-453

  Cutrone, John A ^b   Yospur, Lisa Shane ^b   Khalkhali, Iraj ^a   Tolmos, Jorge ^b   Devito, Alessandro ^b   Diggles, Linda ^b   Vargas, Maria Perla ^b   Shitabata, Paul ^b   French, Samuel ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Angiogenesis; Desmoplasia; Scintimammography; Technetium 99m MIBI

Indexed keywords

ACTIN; ALPHA ACTIN; ANTIGEN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ANGIOGENESIS; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BREAST TUMOR; CELL PROLIFERATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL;

BREAST; BREAST DISEASES; BREAST NEOPLASMS; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0031929219     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Abdel-Dayem HM, Scott AM, Macapinlac HA, El-Gazzar AH, Larson SM. In: Freeman LM, ed. Annual Nuclear Medicine 1994. New York; Raven Press, 1994: 181-234.
2. Taillefer R, Robiduox A, Lambert R, Turpin S, LaPerriere J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995;36:1758-1765.
3. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 1994;21:432-435.
4. Okada RD, Glover D, Gaffney T, Williams SJ. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropsyl-isonitrile. Circulation 1988;77:491-498.
5. 99mTc-sestamibi in the presence of total coronary artery occlusion. Am Heart J 1990;119:842-847.
6. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis(2-methoxyisobutylisonitrile) technetium (I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-1838.
7. Crane P, Laliberti R, Heminway S, Thoalen M, Orlandi C. Effect of mitochondrial viability and metabolism on Tc-99m sestamibi myocardial retention. Eur J Nucl Med 1993;20:20-25.
8. Horaker, Russel L, Klenk N. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, an indicator of node metastases and survival in breast cancer. Lancet 1992;340:1120-1124.
9. Visscher DW, DeMattia F, Ottosen S, Sarkar FH, Crissman JD. Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Modern Pathol 1995;8:665-670.
10. Diggles L, Mena I, Khalkhali IJ. Technical aspects of prone dependant breast scintimammography. J Nucl Med Technol 1994;22:165-170.
11. Khalkhali I, Cutrone JA, Mena IG, et al. Scintimammography. The complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995;196:421-426.
12. Weidner N, Semple JP, Welch WR, Folkman J. Tumor Angiogenesis and metastasis-correlation in invasive breast carcinoma. NEJM 1991;324:1-8.
13. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new, significant, and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;340:1875-1887.
14. Obrenovitch A, Monsigny M. Angiogenese tumorale. Pathol Biol 1986;34:189-201.
15. Scopinaro F, Schillaci O, Scarpini M, et al. Technetium-99m-sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994;21:984-987.
16. 99mTc-sestamibi scanning in the breast [Abstract]. Modern Pathol 1995;19A.